Rheumnow Podcast

Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the EULAR 2026 meeting in London.

Join Drs. Bella Mehta, Jack Cush, Janet Pope, and Jon Kay for a focused conversation on the latest in rheumatoid arthritis care from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping RA practice right now.

Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026.

This focused conversation explores new clinical data, evolving treatment strategies, and practical approaches to managing PsA in everyday practice. From advances in biologic and targeted therapies to ongoing challenges in diagnosis, disease monitoring, and patient care, the panel shares key insights and take-home messages that every rheumatology clinician should know.

Tune in for expert perspectives, clinical pearls, and a comprehensive look at what's shaping the future of psoriatic arthritis management.

2026 EULAR Preview
Beyond BMI: Altered Body Composition in Rheumatoid Arthritis
CAR-T For Rheumatoid Arthritis
This Is a Woman’s World: Women's Health in Rheumatic Disease
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Doctor's Orders or Patient's Choice: BACH study findings
Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs
Digital Patient Education in RA
Making Methotrexate More Effective
Are we failing in the treatment of RA-ILD?
Using AI to Predict Progression to RA
Treat to Target Works in Elderly Onset RA
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Improving Referrals for Inflammatory Arthritis
Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease